| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Kalkers, Killestein, and Polman), Rehabilitation Medicine (Drs. de Groot and Lankhorst), Radiology (Drs. Lazeron and Barkhof), and Clinical Epidemiology and Biostatistics (Dr. Adèr), Academisch Ziekenhuis Vrije Universiteit Amsterdam, The Netherlands.
Address correspondence and reprint requests to Dr. N.F. Kalkers, Academisch Ziekenhuis Vrije Universiteit, Dept. of Neurology, Postbox 7057, 1007 MB Amsterdam, the Netherlands; e-mail: nf.kalkers{at}azvu.nl
OBJECTIVE: The MS Functional Composite (MSFC), a recently developed outcome measure for clinical trials, was applied to 240 patients with MS to explore its utility in different subgroups of MS and for comparison with the Expanded Disability Status Scale (EDSS).
METHOD: Three clinical dimensions were examined: arm/hand function, leg function/ambulation, and cognition. Predictions of relative scores on the MSFC and its components in three major MS phenotypes (relapsing-remitting, primary progressive, and secondary progressive) and three strata of disability were developed and tested. Also, correlations with EDSS were calculated and the effect of an external reference population was assessed.
RESULTS: Mean MSFC score was positive in the relapsing-remitting (0.4) and mildly disabled (0.4) groups and negative in the secondary progressive (-0.3), primary progressive (-0.4), and moderately (-0.07) and severely disabled (-1.0) groups. The correlation between EDSS and MSFC was strong (-0.68). EDSS correlated strongly with ambulation in secondary and primary progressive patients and severely disabled patients, moderately with arm/hand function for all analyzed groups, and not at all with cognition. Comparison with an external reference population showed changes in MSFC- and Z-scores, but did not result in altered differences between the subgroups.
CONCLUSION: Our prospective study in subgroups of MS confirmed and extended the construct validity of the MSFC. The MSFC also showed good concurrent validity with the EDSS, and includes information about cognition.
Key words: MS—MS Functional Composite—Expanded Disability Status Scale.
This article has been cited by other articles:
|
|
 |
|
  R. Rudick, C. Polman, J. Cohen, M. Walton, A. Miller, C Confavreux, F. Lublin, M Hutchinson, P. O'Connor, S. Schwid, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite Multiple Sclerosis, August 1, 2009; 15(8): 984 - 997. [Abstract] [PDF]
|
|
|
|
|
|
J. Kragt, B. van Amerongen, J Killestein, C. Dijkstra, B. Uitdehaag, C. Polman, and P Lips Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women Multiple Sclerosis, January 1, 2009; 15(1): 9 - 15. [Abstract] [PDF]
|
|
|
|
|
|
J J Kragt, J M Nielsen, F A. van der Linden, B M. Uitdehaag, and C H Polman How similar are commonly combined criteria for EDSS progression in multiple sclerosis? Multiple Sclerosis, November 1, 2006; 12(6): 782 - 786. [Abstract] [PDF]
|
|
|
|
 |
|
 V. de Groot, H. Beckerman, B. M. J. Uitdehaag, H. C. W. de Vet, G. J. Lankhorst, C. H. Polman, and L. M. Bouter The usefulness of evaluative outcome measures in patients with multiple sclerosis Brain, October 1, 2006; 129(10): 2648 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J Kragt, F A. van der Linden, J M Nielsen, B M. Uitdehaag, and C H Polman Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 594 - 598. [Abstract] [PDF]
|
|
|
|
|
|
M M Nieuwenhuis, H Van Tongeren, P S Sorensen, and M Ravnborg The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 495 - 500. [Abstract] [PDF]
|
|
|
|
 |
|
 M. E. Shy, J. Blake, K. Krajewski, D. R. Fuerst, M. Laura, A. F. Hahn, J. Li, R. A. Lewis, and M. Reilly Reliability and validity of the CMT neuropathy score as a measure of disability Neurology, April 12, 2005; 64(7): 1209 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Ravnborg, M Blinkenberg, F Sellebjerg, M Ballegaard, S H. Larsen, and P S. Sorensen Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale Multiple Sclerosis, February 1, 2005; 11(1): 81 - 84. [Abstract] [PDF]
|
|
|
|
|
|
H Coo, W M Hopman, C M Edgar, E V McBride, and D G Brunet The Paced Auditory Serial Addition Test: to what extent is it performed as instructed, and is it associated with disease course? Multiple Sclerosis, February 1, 2005; 11(1): 85 - 89. [Abstract] [PDF]
|
|
|
|
|
|
K. Rejdak, M. J. Eikelenboom, A. Petzold, E. J. Thompson, Z. Stelmasiak, R. H.C. Lazeron, F. Barkhof, C. H. Polman, B. M.J. Uitdehaag, and G. Giovannoni CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis Neurology, October 26, 2004; 63(8): 1439 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E L. Hoogervorst, J N. Zwemmer, B Jelles, C H Polman, and B M. Uitdehaag Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability Multiple Sclerosis, October 1, 2004; 10(5): 569 - 574. [Abstract] [PDF]
|
|
|
|
 |
|
 C McGuigan and M Hutchinson The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure J. Neurol. Neurosurg. Psychiatry, February 1, 2004; 75(2): 266 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Hobart, N Kalkers, F Barkhof, B Uitdehaag, C Polman, and A Thompson Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite Multiple Sclerosis, February 1, 2004; 10(1): 41 - 46. [Abstract] [PDF]
|
|
|
|
|
|
E L. Hoogervorst, N F Kalkers, G R Cutter, B M. Uitdehaag, and C H Polman The patient's perception of a (reliable) change in the Multiple Sclerosis Functional C omposite Multiple Sclerosis, February 1, 2004; 10(1): 55 - 60. [Abstract] [PDF]
|
|
|
|
|
|
A. J Thompson Developing clinical outcome measures in multiple sclerosis: an evolving process Multiple Sclerosis, October 1, 2002; 8(5): 357 - 358. [PDF]
|
|
|
|
|
|
R A Rudick, G Cutter, and S Reingold The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials Multiple Sclerosis, October 1, 2002; 8(5): 359 - 365. [Abstract] [PDF]
|
|
|
|
|
|
B M. Uitdehaag, H J Ader, T J. Roosma, V de Groot, N F Kalkers, and C H Polman Multiple sclerosis functional composite: impact of reference population and interpretation of changes Multiple Sclerosis, October 1, 2002; 8(5): 366 - 371. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Cohen, G. R. Cutter, J. S. Fischer, A. D. Goodman, F. R. Heidenreich, M. F. Kooijmans, A. W. Sandrock, R. A. Rudick, J. H. Simon, N. A. Simonian, et al. Benefit of interferon {beta}-1a on MSFC progression in secondary progressive MS Neurology, September 10, 2002; 59(5): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Petzold, M. J. Eikelenboom, D. Gveric, G. Keir, M. Chapman, R. H. C. Lazeron, M. L. Cuzner, C. H. Polman, B. M. J. Uitdehaag, E. J. Thompson, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations Brain, July 1, 2002; 125(7): 1462 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. J. Hoogervorst, N. F. Kalkers, B. M. J. Uitdehaag, and C. H. Polman A Study Validating Changes in the Multiple Sclerosis Functional Composite Arch Neurol, January 1, 2002; 59(1): 113 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Kalkers, E. Bergers, J. A. Castelijns, M. A. A. van Walderveen, J. C. J. Bot, H. J. Ader, C. H. Polman, and F. Barkhof Optimizing the association between disability and biological markers in MS Neurology, October 9, 2001; 57(7): 1253 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E L. Hoogervorst, N F Kalkers, L M. van Winsen, B M. Uitdehaag, and C H Polman Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 335 - 339. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Rudick, G. Cutter, M. Baier, E. Fisher, D. Dougherty, B. Weinstock-Guttman, M. K. Mass, D. Miller, and N. A. Simonian Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS Neurology, May 22, 2001; 56(10): 1324 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L.J. Hoogervorst, L.M.L. van Winsen, M.J. Eikelenboom, N.F. Kalkers, B.M.J. Uitdehaag, and C.H. Polman Comparisons of patient self-report, neurologic examination, and functional impairment in MS Neurology, April 10, 2001; 56(7): 934 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.F. Kalkers, L. Bergers, V. de Groot, R.H.C. Lazeron, M.A.A. van Walderveen, B.M.J. Uitdehaag, C.H. Polman, and F. Barkhof Concurrent validity of the MS Functional Composite using MRI as a biological disease marker Neurology, January 23, 2001; 56(2): 215 - 219. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
